Nabriva Therapeutics (NBRV) Downgraded by BidaskClub
BidaskClub cut shares of Nabriva Therapeutics (NASDAQ:NBRV) from a sell rating to a strong sell rating in a report released on Friday.
A number of other brokerages have also commented on NBRV. Cantor Fitzgerald set a $16.00 price objective on shares of Nabriva Therapeutics and gave the stock a buy rating in a report on Wednesday, May 30th. Needham & Company LLC restated a buy rating and set a $18.00 price objective on shares of Nabriva Therapeutics in a report on Wednesday, July 25th. Bank of America set a $5.00 price objective on shares of Nabriva Therapeutics and gave the stock a buy rating in a report on Monday, August 27th. Zacks Investment Research lowered shares of Nabriva Therapeutics from a buy rating to a hold rating in a report on Thursday, July 19th. Finally, Morgan Stanley initiated coverage on shares of Nabriva Therapeutics in a report on Friday, September 7th. They set an overweight rating and a $8.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company. The company currently has a consensus rating of Buy and a consensus target price of $11.67.
Shares of NASDAQ:NBRV opened at $2.53 on Friday. Nabriva Therapeutics has a 12 month low of $2.33 and a 12 month high of $8.58. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 0.01. The firm has a market cap of $1.68 billion, a P/E ratio of -1.02 and a beta of 1.51.
In other Nabriva Therapeutics news, Director Daniel D. Burgess purchased 36,000 shares of the stock in a transaction on Tuesday, July 31st. The shares were purchased at an average cost of $2.75 per share, for a total transaction of $99,000.00. Following the purchase, the director now owns 36,000 shares of the company’s stock, valued at $99,000. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 2.79% of the stock is currently owned by insiders.
Hedge funds have recently modified their holdings of the business. Wedbush Securities Inc. acquired a new stake in Nabriva Therapeutics in the 2nd quarter valued at $371,000. Trexquant Investment LP acquired a new stake in Nabriva Therapeutics in the 1st quarter valued at $244,000. DRW Securities LLC acquired a new stake in Nabriva Therapeutics in the 1st quarter valued at $106,000. Prosight Management LP increased its stake in Nabriva Therapeutics by 73.6% in the 2nd quarter. Prosight Management LP now owns 421,414 shares of the biotechnology company’s stock valued at $1,467,000 after buying an additional 178,725 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in Nabriva Therapeutics by 173.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 111,865 shares of the biotechnology company’s stock valued at $563,000 after buying an additional 70,917 shares during the last quarter. Hedge funds and other institutional investors own 52.53% of the company’s stock.
About Nabriva Therapeutics
Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.
Read More: What is a Leveraged Buyout (LBO)?
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.